In contrast to CD28 signaling, SLAMF7 engagement reduced IL-10 secretion, a cytokine with well-established immunosuppressive functions, as well as IL-6 levels, which has been implicated in inflammation-driven tumor progression (55–58). Here, IL6 is linked to neoplasm.